Barlow Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.01M Buy
2,599
+1,151
+79% +$1.36M 0.31% 36
2026
Q2
$1.76M Hold
1,448
– – 0.19% 45
2026
Q1
$1.34M Buy
1,448
+13
+0.9% +$13.2K 0.15% 45
2025
Q4
$1.53M Buy
1,435
+95
+7% +$90.8K 0.16% 46
2025
Q3
$1.09M Buy
1,340
+391
+41% +$291K 0.12% 56
2025
Q2
$740K Sell
949
-20,416
-96% -$15.9M 0.09% 65
2025
Q1
$18.9M Buy
21,365
+20,279
+1,867% +$16.9M 2.48% 16
2024
Q4
$811K Sell
1,086
-945
-47% -$782K 0.1% 65
2024
Q3
$1.82M Hold
2,031
– – 0.24% 51
2024
Q2
$1.75M Hold
2,031
– – 0.24% 51
2024
Q1
$1.53M Hold
2,031
– – 0.21% 59
2023
Q4
$1.18M Buy
+2,031
New +$1.19M 0.17% 64

Other funds holding LLY

Barlow Wealth Partners's LLY Position: Q3 2026 in Review

Barlow Wealth Partners increased its Eli Lilly (LLY) stake by 79% in Q3 2026, buying an estimated $1.36M and bringing the position to 2,599 shares worth $3.01M. The position accounts for 0.31% of the portfolio, ranked #36.

Barlow Wealth Partners first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $18.9M in Q1 2025. 2,091 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Barlow Wealth Partners held 2,599 shares of Eli Lilly worth $3.01M as of Q3 2026.
  • Barlow Wealth Partners bought 1,151 Eli Lilly shares in Q3 2026, an estimated $1.36M.
  • Eli Lilly made up 0.31% of Barlow Wealth Partners's portfolio in Q3 2026, its #36 holding.
  • Barlow Wealth Partners first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • Barlow Wealth Partners's Eli Lilly position peaked at $18.9M in Q1 2025.
  • 2,091 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Barlow Wealth Partners's 13F filing for Q3 2026, filed 15 Oct 2026.